Histone H1/MBP hydrolysing antibodies - novel potential marker in diagnosis of disease severity in systematic lupus erythematosus patients


Recently we have shown the presence of catalytically active IgGs, capable to cleave histone H1 and bovine myelin basic protein (MBP), in blood serum of SLE patients. Here we present data that demonstrate the correlation between a) proteolytic activity towards histone H1 and MBP of IgG-antibodies from blood serum of SLE patients and b) disease severity level in these patients. IgGs were isolated from blood serum by chromatography on protein G-sepharose. Commercial preparations of bovine myelin basic proteins (MBP) and calf thymus histone H1 were used as substrates. Analysis of the proteolytic activity showed that 16 of 38 lgG-preparations (42,1%) obtained from blood serum of SLE patients were capable of cleaving both histone H1 and MBP with different efficiency. It was revealed that the presence in blood serum of lgGs possessing proteolytic activity towards both histone H1 and bMBP closely correlates with manifestation of the disease severity in SLE patients.

Share and Cite:

Chopyak, V. , Tolstiak, Y. , Magoryvska, I. , Bilyy, R. , Bilyy, R. , Korniy, N. , Kit, Y. and Stoika, R. (2010) Histone H1/MBP hydrolysing antibodies - novel potential marker in diagnosis of disease severity in systematic lupus erythematosus patients. Health, 2, 1204-1207. doi: 10.4236/health.2010.210177.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Cervera, R., Khamashta, M.A., Font, J., Sebastiani, G.D., Gil, A., Lavilla, P., Mejía, J.C., Aydintug, A.O., Chwa- linska-Sadowska, H., de Ramón, E., Fernández-Nebro, A., Galeazzi, M., Valen, M., Mathieu, A., Houssiau, F., Caro, N., Alba, P., Ramos-Casals, M., Ingelmo, M. and Hughes, G.R. (2003) European working party on systemic lupus erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period. A comparison of early and late matifestation in a cohort of 1, 000 patients. M
[2] Uramoto, K.M., Michet, C.J., Thumboo, J. Sunku, J., O’Fallon, W.N. and Gabriel, S.E. (1999) Trends in the incidence and mortality of systemic lupus erytemathosus, 1950-1992. Arthritis & Rheumatism, 42(1), 46-50.
[3] Pons-Estel, B.A., Catoggio, L.J., Cardiel, M.H., Soriano, E.R., Gentiletti, S., Villa, A.R., Abadi, I., Caeiro, F., Alvarellos, A. and Alarcón-Segovia, D. (2004) Grupo latinoamericano de estudio del lupus. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythe- matosus: Ethnic and disease heterogeneity among ‘His- panics’, Medicine (Baltimore), 83(1), 1-17.
[4] Boddaert, J., Huong, D.L., Amoura, Z., Wechsler, B., Godeau, P. and Piette, J.C. (2003) Late-onset systemic lupus erythematosus. A personal series of 4 patients and pooled analisis of 714 cases in the literature. Medicine (Baltimore), 83(6), 348-359.
[5] Karlson, E.W., Daltroy, L.H., Lew, R.A., Wright, E.A., Partridge, A.J., Fossel, A.H., Roberts, W.N., Stern, S.H., Straaton, K.V., Wacholtz, M.C., Kavanaugh, A.F., Grosflam, J.M. and Liang, M.H. (1997) The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis & Rheumatism, 40(1), 47-56.
[6] To, C.H., Mok, C.C., Tang, S.S., Ying, S.K., Wong, R.W. and Lau, C.S. (2009) Prognostically distinct clinical patterns of systemic lupus erythematosus identified by cluster analysis. Lupus, 18(14), 1267-1275.
[7] Bach, J.F., Koutouzow, S. and van Endert, P.M. (1998) Are there unigue autoantigents triggering autoimmune diseases? Immunological Reviews, 164(1), 139-155.
[8] Kurien, B.T. and Scofield, R.H. (2006) Autoantibody determination in the diagnosis of systemic lupus eryth- ematosus. Scandinavian Journal of Immunology, 64(3), 227-235.
[9] Nezlin, R., Alarcyn-Segovia, D. and Shoenfeld, Y. (1998) Immuno-chemical determination of DNA in immune complexes present in the circulation of patients with systemic lupus erythematosus. Journal of Autoimmunity, 11(5), 489-493.
[10] Schett, G., Smole, J., Zimmermann, C., Hiesberger, H., Hoefler, E., Fournel, S., Muller, S., Rubin, R.L. and Steiner, G. (2002) The autoimmune response to chromatin antigens in systemic lupus erythematosus: Autoantibodies against histone Н1 are a highly specific marker for SLE associated with increased disease activity. Lupus, 11(11), 704-715.
[11] Gabibov, A.V. Ponomarenko, N.A., Tretyak, E.B., et al. (2006) Catalic autoantibodies in clinical autoimmunity and modern medicine. Autoimmunity Reviews, 5(5), 324-330.
[12] Gabibov, A.G., Kozyr, A.V., Kolesnikov, A.V. and Suchkov, S.V. (2000) Disease association and cytotoxic effects of DNA-hydrolyzing autoantibodies. Chemical Immunology, 77, 130-156.
[13] Kozyr, A.V. and Gabibov, A.G. (2009) DNA-hydro- lyzing AB: is catalytic activity a clue for physiological significance? Autoimmunity, 42(4), 359-361.
[14] Kit, I., Mahorivs’ka, I.R., Havryliuk, A.M., Chhop’iak, V.V., Bily?, R.O. and Sto?ka, R.S. (2009) Proteolytic activity of blood serum IgG in patients with systemic lupus erythematosis. Ukr Biokhim Zh., 81(3), 77-83.
[15] Kit, Y.Y., Starykovich, M.A., Richter, V. A. and Stoika, R.S. (2008) Detection and characterization of IgG- and sIgA-Abzymes capable of hydrolyzing Histone H1. Biochemistry (Moscow), 73(8), 950-956.
[16] Magorivska, I., Bilyy, R., Shalay, O., Loginsky, V., Kit, Y. and Stoika, R. (2009) Blood serum immunoglobulings of patients with multiple myeloma are capable of hy- drolizing histone H1. Experimental Oncology, 31(2), 97-101.
[17] Magorivska, I.B., Bilyy, R.O., Havrylyuk, A.M., Chop’- yak, V.V., Stoika, R.S. and Kit, Y.Y. (2010) Anti-histone H1 IgGs from blood serum of systemic lupus erythe- matosus patients are capable of hydrolyzing histone H1 and myelin basic protein. Journal of Molecular Recog- nization, 23(5), 495-502.
[18] Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227(5259), 680-685.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.